A novel tumor suppressor gene, PTEN/MMAC1, has been recently shown to be mutated in gliomas, breast, prostate, kidney cancers and melanomas. Loss-ofheterozygosity studies in melanoma have suggested the presence of at least one chromosome 10q locus lost early in tumor progression. In this study, we screened 45 melanoma cell lines and 17 paired uncultured metastatic melanoma and peripheral blood specimens for PTEN/ MMAC1 alterations using PCR-SSCP and direct sequencing. We found nine melanoma cell lines with homozygous deletions (®ve with intragenic loss) and four cell lines with mutations (one nonsense and one frameshift; two intronic); from among our uncultured melanoma specimens, we found one tumor with a somatic 17 bp duplication in exon 7 leading to a premature stop codon and one tumor with a possible homozygous deletion. Furthermore, we have identi®ed a novel intragenic polymorphism within intron 4 of PTEN/ MMAC1. Taken together, these data suggest that PTEN/MMAC1 may be a chromosome 10q tumor suppressor important in melanoma tumor formation or progression.
Introduction
Deletions in chromosome 10q region have been described for various tumors but are particularly common in gliomas (Fults et al., 1990; Rasheed et al., 1992) . Allelic losses involving chromosome 10q in glioblastoma multiforme are so extensive and frequent that no consistent chromosomal sublocalization has been de®ned by loss-of-heterozygosity studies (LOH) (Fults et al., 1990) . One potential implication of these ®ndings is that other tumor suppressors are located on 10q. Indeed, Steck and colleagues reported evidence for two distinct suppressive loci on chromosome 10 (10pter-q11 and 10q24-26) that are involved in glioma progression (Steck et al., 1995) . Furthermore, Albarosa and associates found two intervals (4-cM LOH region anked by D10S221 and D10S209; 17-cM LOH region anked by D10S221 and D10S214) that appear deleted in gliomas (Albarosa et al., 1996) . Taken together, these data point to the possibility of several tumor suppressor genes on 10q that may be involved in glial neoplasm.
Based on the positional data accrued from gliomas, several groups have recently identi®ed a novel tumor suppressor located on chromosome 10q23. This gene has various designations including PTEN, , MMAC1 (Steck et al., 1995) and TEP1 (Li and Sun, 1997) . Although PTEN/MMAC1 has been shown to be frequently altered in primary gliomas and glioma cell lines, its involvement in other advanced tumors, such as prostate, breast and kidney has also been demonstrated Steck et al., 1995) . Furthermore, mutations in PTEN/MMAC1 have also been identi®ed in the germline of patients with Cowden's syndrome . This rare autosomal dominant disease is characterized by hamartomas of numerous organ systems (e.g. skin, breast, thyroid, gastrointestinal) and malignancies of breast, thyroid and brain (Shapiro et al., 1988) . Detection of mutations in both sporadic cancers and the germline of patients with Cowden's disease has ®rmly established PTEN/MMAC1 as a bona ®de tumor suppressor gene.
Glioblastoma and melanoma are both neuroectodermal derivatives and they exhibit several genetic similarities. First, they both exhibit a high rate of p16/ CDKN2A abnormalities (Bartkova et al., 1996; Dreyling et al., 1995; Hussussian et al., 1994; Kamb et al., 1994) . p16/CDKN2A has been shown to be critical in regulating cell cycle progression through the G1-S juncture (Sherr, 1996; Sherr and Roberts, 1995) . Second, both gliomas and melanomas exhibit a high frequency of loss of 10q (Healy et al., 1995 (Healy et al., , 1996 Herbst et al., 1994; Parmiter et al., 1988; Richmond et al., 1986) . Alterations in one region, chromosome 10q22-10qter, has been frequently documented in sporadic melanoma; however, precise positional information is still lacking. Cytogenetic data suggest involvement of chromosome 10q24-26 in early melanocytic dysplasia (Parmiter et al., 1988; Richmond et al., 1986) while LOH studies in melanoma have also con®rmed the frequent early loss of 10q alleles (Healy et al., 1995 (Healy et al., , 1996 Herbst et al., 1994) . In an initial screen of four primary melanomas (one with LOH on 10q), no mutations in PTEN/MMAC1 were detected (Steck et al., 1997) . However (Guldberg et al., 1997) recently reported mutations in about 40% of melanoma cell lines. We set out to assess for changes in PTEN/MMAC1 from a larger panel of melanoma tumor cell lines, uncultured metastatic melanomas and germline DNA from patients with a family history of melanoma. Our data suggest that this novel phosphotyrosine phosphatase may be an important tumor suppressor involved in melanoma tumorigenesis.
Results

PTEN/MMAC1 mutations in melanoma cell lines, uncultured melanoma specimens
Using PCR-SSCP analysis, we screened for mutations in exons 1 through 9 of PTEN/MMAC1 from 45 melanoma cell lines, 17 paired cutaneous melanoma and peripheral blood samples and germline DNA from 28 melanoma patients with a family history of melanoma. Table 1 enumerates all the identi®ed mutations. We found four mutations (4/45 or 9%) from among our melanoma cell lines and one mutation from among our uncultured metastatic melanomas. Figure 1a shows an SSCP abnormality in the melanoma cell line, UACC 903A. Upon sequencing, this shifted band was found to be due to a T-to-G transition at the third position of codon 76 (TAT?TAG) which creates a premature stop codon (Figure 1b) . Line SK-Mel 39 harbors a single base insertion at codon 183 leading a stop codon at position 189. Line WM-J6 carries a G-to-T substitution within the 5' consensus splice sequence (GTAAGT?GTAATT) of intron 6 and line SKMel 131 contains a T-to-A substitution within the 5' consensus splice sequence (GTAA?GAAA). In all melanoma lines with mutations, the SSCP shift patterns and sequencing results demonstrate homozygosity for the abnormal allele (data not shown).
In one of our uncultured cutaneous melanomas, an apparent somatic insertion within exon 7 of PTEN/ MMAC1 was found ( Figure 2a) ; the insertion was not present in peripheral blood DNA from the patient. We cloned both alleles and demonstrated a heterozygous 17 bp (CTTCCACAAACAGAACA) duplication at codon 263 creating a novel stop codon at 271 ( Figure  2b ). This sample demonstrates LOH using the intragenic polymorphism described below (data not shown).
From our peripheral blood DNA samples from melanoma patients, we identi®ed a novel polymorphism within intron 4 ( Figure 3 ). We have designated this polymorphic 5 bp insertion as follows:
Homozygous deletions of PTEN/MMAC1. Several samples demonstrated an absence of speci®c PCR products (e.g. Lanes 4 and 8, Figure 1a ). This suggests homozygous deletions and we con®rmed our SSCP ®ndings with duplex (using a 535 bp fragment of the dystrophin gene as control) and multiplex PCR (using retained exons as controls). A representative intragenic deletional map is shown in Figure 4 . Cell line BA-1 has no detectable signal in exons 2, 3, 4 and 5 while the remaining exons are intact. Table 1 lists other cell lines with intragenic deletions. In four of our lines (SK-Mel 23, ML, WK, WM168.26), the entire gene appears deleted (data not shown).
Using microsatellite markers D10S215, D10S583, D10S541 and PTEN4(+5), we identi®ed one uncultured metastatic melanoma sample (KM-16) with apparent retention of heterozygosity ( Figure 5 ). Since the retained intragenic alleles are¯anked by regions of LOH, this sample is most likely homozygously deleted for PTEN/MMAC1.
Discussion
In this study, we found PTEN/MMAC1 to be altered in approximately 29% (9 HD and four mutations out of 45 lines) of melanoma cell lines. Guldberg et al. reported an overall rate of 40% in their series of melanoma cell lines (9 HD and six mutations out of 35 lines) (Guldberg et al., 1997) . How do these rates of PTEN/MMAC1 alterations in melanoma compare with the rates of change in other tumor types? Li et al. reported an overall frequency (including homozygous deletions, frameshift, and nonsense mutations) of 63% (5/8) in glioblastoma cell lines, 100% (4/4) in prostate cancer cell lines, 10% (2/20) in breast cancer cell lines, 24% (8/34) in glioblastoma xenografts, 5% (2/40) of breast cancer xenografts and 17% (3/18) of primary glioblastomas . Steck et al. found a mutation rate of 60% (10/17) in glioma cell lines, 33% (1/3) in prostate cell lines, 23% (6/26) of primary (Risinger et al., 1997) . Neither sporadic thyroid tumors nor primary breast carcinomas (Rhei et al., 1997) appear to harbor PTEN/MMAC1 mutations. Clearly, the frequency of alteration in melanomas is lower than that observed in glioblastomas and endometrial cancers. As with other tumor suppressors, there is a selectivity of tissue type with tumor formation. Our mutations create premature termination codons and therefore truncated proteins. The nonsense mutation at codon 76 deletes the phosphatase domain Steck et al., 1997) while the insertion at codon 183 eliminates approximately half of the open reading frame. If the phosphatase domain is essential for the tumor suppressive function of PTEN/ MMAC1, the Tyr76Stop mutation abrogates the function of this protein. Two mutations fall within the 5-consensus splice sequence of introns and therefore would have potential splicing defects. The 17 bp duplication leads to a new protein with a frameshifted sequence starting at codon 263 and a novel stop codon at 271. Since the C-terminus has no homology with any known genes, the functional consequences are dicult to predict. Terminating and deletional mutations appear to be more prevalent in the N-terminus as compared to the C-terminus Steck et al., 1997) . Some have speculated that the N-terminus may be functionally more important or that the C-terminus encodes functionally redundant domains (Steck et al., 1997) . Alternatively, the C-terminus may be essential for the survival of the cell and mutations in this region are incompatible with viability. Even though the frequency of genetic alterations among our cultured melanomas is higher than among our uncultured metastatic melanoma specimens, PTEN/MMAC1 involvement in melanoma tumor formation is unlikely a pure in vitro phenomenon. We have provided direct evidence for a deleterious mutation and suggestive evidence for another homozygous deletion in our uncultured samples. Given the limited quantities of DNA available, we were not able to complete Southern blot analysis of our uncultured tumors. Using the PTEN4(+5) marker, we found a 44% (4/9) rate of LOH from our 17 paired samples (data not shown). Three of these hemizygous tumors did not reveal mutations by our techniques. Mutations may have gone undetected using our PCR-SSCP analysis or other modes of inactivation (e.g. methylation) may occur. Evidence from (Guldberg et al., 1997) also supports the notion that uncultured metastatic melanomas contain bona ®de mutations: they were able to demonstrate the same mutations, for three of their cases, in both cell lines and its parent metastases.
Is PTEN/MMAC1 the target of 10q22-qter losses in melanoma? In favor of this hypothesis is the detection of speci®c mutations that have functional consequences; in particular, we have demonstrated intragenic homozygous deletions in several samples. In addition, all of the point mutations appear homozygous in the melanoma cell lines, consonant with the two-hit hypothesis, thus supporting the view that this gene is a target of 10q LOH. However, a review of the 10q LOH data in melanoma suggests an additional locus may be more distal on 10q than PTEN/ MMAC1. Walker et al. found that the frequency of allelic loss in chromosome 10q markers ranges from 26% at D10S254 to 32% at D10S212 (Walker et al., 1995) . They delimited the smallest region of overlap (SRO) to a 36cM area distal to D10S254. PTEN/ MMAC1 is near D10S215 , which is proximal to the published SRO. Similarly, Albarosa et al. identi®ed a 17-cM region,¯anked by D10S221 and D10S214, that was commonly deleted in gliomas (Albarosa et al., 1996) ; this interval is telomeric to PTEN/MMAC1. For melanomas, Walker et al. demonstrated that the marker closest to PTEN/ MMAC1 (D10S215) showed 18% LOH while thē anking markers both revealed higher rates of allelic loss (21% for D10S464 proximally and 26% for D10S254 distally) (Walker et al., 1995) . Thus, there may be multiple tumor suppressor genes on chromosome 10q and PTEN/MMAC1 represents one of these genes. Alternatively, the retention of heterozygosity near PTEN/MMAC1 may signify homozygous deletions of this gene within the tumor. Further studies are needed to either con®rm PTEN/MMAC1 as the 10q22-qter melanoma tumor suppressor or identify other tumor suppressors in this region.
How do PTEN/MMAC1 mutations ®t into a stepwise model of melanoma tumor progression? Using LOH data, Healy et al. have suggested that 9p loss occurs early followed by 10q loss after the melanoma has become invasive (Healy et al., 1995) . Furthermore, losses on both chromosomes are frequently seen concomitantly suggesting that genes on 9p and 10q lie on distinct pathways (Healy et al., 1995; Walker et al., 1995) . It is interesting to note that in most of our cell lines that exhibit PTEN/MMAC1 alterations, either p16/CDKN2A or CDK4 has also been shown to be altered (Table 1) . Taken together, these data suggest that insults to both the Rb pathway and the PTEN/MMAC1 pathway may contribute to the development of melanoma. The PTEN/MMAC1 protein has sequence homologies to other phosphotyrosine phosphatases and the cytoskeletal protein, tensin (Li and Sun, 1997; Steck et al., 1997) . PTEN/MMAC1's phosphatase activity, its regulation by TGF-b, and its cytoplasmic localization was recently demonstrated by Li and Sun (Li and Sun, 1997) . Beyond these ®ndings, the intracellular substrates for PTEN/MMAC1 and the functional consequences of its loss remain highly speculative. Phosphotyrosine kinases have long been known to be oncogenic when activated. In Xiphophorus ®sh, overexpression of a receptor tyrosine kinase, Xmrk, and the abrogation of a repressor, R, leads to the formation of melanomas (Friend, 1993) . Thus, the gene at the R locus may encode a PTEN/MMAC1-like molecule. Conversely, a tyrosine kinase, like Xmrk, may play a role in human melanomas. Up to now, the connection between tyrosine phosphorylation and melanoma has been unsubstantiated. However, the cloning of the PTEN/MMAC1 tyrosine phosphatase and the identi®cation of mutations in melanoma tumors suggest that aberrant tyrosine phosphorylation of critical substrates may play a role in melanoma formation or progression.
In summary, we have identi®ed alterations of PTEN/MMAC1 in melanoma. These ®ndings con®rm the existence of at least one melanoma tumor suppressor gene on chromosome 10q22-10qter. Furthermore, a more direct role for phosphotyrosine phosphorylation in melanoma tumorigenesis can be established.
Materials and methods
Cell lines
Melanoma tumor cell lines have been previously described (Fountain et al., 1992) . The following investigators generously oered cell lines for this research; WM lines were obtained from Dr M Herlyn from the Wistar Institute, Philadelphia, Pennsylvania; LH, ML, RU, AN and WK lines were obtained from Dr R Byers from Boston University Medical Center, Boston, Massachusetts; paired DNA samples of uncultured metastatic melanomas (Ohta et al., 1996) and autologous peripheral blood specimens were obtained from Dr K Huebner, Kimmel Cancer Center, Philadelphia, Pennsylvania. Germline DNA from melanoma patients with a biopsy-proven family history of melanoma have been previously published (FitzGerald et al., 1996) .
SSCP analyses
High molecular weight DNA was extracted from tissue culture samples using standard phenol/chloroform protocols. DNA fragments were prepared by PCR and subjected to single strand conformation polymorphism analysis (SSCP) for the detection of sequence alterations. Genomic primers for the nine exons of the human PTEN/MMAC1 gene have been previously published (Steck et al., 1997) . Primers (40 pmol) were labeled using T4 polynucleotide kinase (New England Biolabs) and 32 P-g-ATP (Dupont/ New England Nuclear) for 30 min at 308C. PCR reactions were performed using end-labeled primers under standard conditions (1 mM cold primer/0.09 mM 32 P-labeled primer; 10 mM Tris-HCl, pH 8.3; 50 mM KCl; 2.5 mM MgCl 2 ; 0.001% gelatin; 200 mM dNTP), 10 ml reactions were performed in an MJ thermocycler: 35 cycles of 958C for 30 s, 558C for 30 s, and 728C for 45 s. Upon completion of the reactions, 25 ml of stop solution (95% formamide, 10 mM EDTA, 0.1% BPB, 0.1% XC) was added. The reaction was heated to 958C for 5 min, cooled immediately on ice for 5 min, and then allowed to come to room temperature. For analysis, 3 ml of each sample was loaded on an 0.56MDE (FMC Bioproducts)/5% glycerol gel, and subjected to 6.0 watts at room temperature for approximately 12 h. Gels were then dried and exposed to autoradiography ®lm at room temperature or 7808C for 2 to 12 h.
Homozygous deletions in the PTEN/MMAC1 gene were detected by PCR analyses of genomic DNA using the previously described primers (Steck et al., 1997) . Absence of speci®c bands observed during SSCP analyses were con®rmed using a duplex PCR reaction with PM-1 (Research Genetics; PM-1 is a 535 bp fragment of the dystrophin gene, which maps to the X-chromosome) as a control. Specimens which had intragenic deletions of speci®c PTEN/MMAC1 exons were re-tested using multipled PCR reactions with both PM-1 and retained PTEN/MMAC1 exons. Products were visualized on a 1.5% agarose gels stained with ethidium bromide.
Loss of heterozygosity studies
DNA from paired cutaneous melanoma were subjected to ampli®cation using microsatellite markers D10S215, D10S583, D10S541 (Research Genetics) and PTEN/ MMAC1 exon 4 primers [F: GGG GGT GAT AAC AGT ATC TA; R: CTT TAT GCA ATA CTT TTT CCT A]. PCR reactions were performed under standard conditions (1 mM cold primer; 2 mCi [a-32 P]dCTP; 10 mM Tris-HCl, pH 8.3; 50 mM KCl; 2.5 mM MgCl 2 ; 0.001% gelatin; 200 mM dNTP), 10 ml reactions were performed in an MJ thermocycler: 35 cycles of 958C for 30 s, 558C for 30 s, and 728C for 45 s. Products were subjected to denaturing electrophoresis using Sequagel TM (National Diagnostics), dried onto ®lter paper and autoradiographed overnight without a screen at room temperature.
DNA sequencing
Samples demonstrating aberrant bands by SSCP were selected for sequence analysis. DNA fragments of mutant exons were prepared by standard PCR and puri®ed using the QIAquick Gel Extraction Kit (Qiagen) according to the manufacturer's speci®cations. Puri®ed PCR products were directly subject to dsDNA Cycle Sequencing System (Gibco BRL) using 32 P-end-labeled PTEN/MMAC1 primers. Gels were dried and autoradiographed at room temperature overnight. The insertion in the melanoma tissue sample was ®rst cloned into the TA vector (pCR2.1 TM ; Invitrogen) and subsequently sequenced as described above.
Abbreviations SSCP, single strand conformation polymorphism; LOH, loss-of-heterozygosity; MM, malignant melanoma
